SCHEDULE 13G/A: Citadel Entities Disclose Significant Stake in VYNE Therapeutics, Kenneth Griffin's Beneficial Ownership Reaches 7.2%
Beneficial Ownership Disclosure
Citadel Advisors LLC, Citadel Securities LLC, and affiliated entities, along with Kenneth Griffin, have disclosed their beneficial ownership in VYNE Therapeutics Inc., with Griffin's aggregate stake reaching 7.2% of the common stock.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 1,040,070 shares of VYNE Therapeutics Inc. common stock, representing 6.8% of the class.
- Citadel Securities LLC beneficially owns 58,260 shares, accounting for 0.4% of the outstanding common stock.
- Citadel Securities Group LP and Citadel Securities GP LLC each beneficially own 60,259 shares, also representing 0.4% of the class.
- Kenneth Griffin, through his controlling interests in various Citadel entities, is deemed to beneficially own an aggregate of 1,100,329 shares, which constitutes 7.2% of VYNE Therapeutics Inc.'s common stock.
- All reported shares are held with shared voting and shared dispositive power by the respective reporting persons.
- The percentages are based on 15,209,862 shares outstanding as of February 27, 2025, as reported in the issuer's Form 10-K filed on March 6, 2025.
- The filing is an Amendment No. 2 to Schedule 13G, indicating previous ownership disclosures.
- The Reporting Persons certify that the securities were not acquired or held for the purpose of changing or influencing the control of VYNE Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or forward-looking statements that would indicate a positive or negative sentiment. It is neutral.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant institutional investment firm, Citadel, has maintained or adjusted its stake in VYNE Therapeutics Inc., a company in the biotechnology or pharmaceutical sector. Such disclosures provide transparency regarding major shareholders and can signal institutional confidence or interest in the company's prospects within its industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity. The presence of a major institutional investor like Citadel may be viewed positively by other investors.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date as of which 15,209,862 shares of VYNE Therapeutics Inc. common stock were outstanding, according to the issuer's Form 10-K. |
| 03/06/2025 | Date VYNE Therapeutics Inc. filed its Form 10-K with the SEC, providing the shares outstanding figure. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 05/15/2025 | Date of filing for this Schedule 13G Amendment No. 2. |
Keywords
VYNE Therapeutics Inc., Citadel Advisors LLC, Citadel Securities LLC, Kenneth Griffin, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.